BCA-101 is under clinical development by Bicara Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect BCA-101’s likelihood of approval (LoA) and phase transition for Pancreatic Cancer took place on 18 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BCA-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
BCA-101 is under development for the treatment of solid tumors like squamous cell lung cancer (SqCLC), squamous cell carcinoma of the head and neck (HNSCC), RAS wild-type microsatellite stable Colorectal carcinoma (RAS WT MSS CRC), squamous cell carcinoma of the anal canal (SCCAC), glioblastoma (GBM), gastric cancer, and any solid tumor with a KRAS G12D or G13D mutation any solid tumor with EGFR amplification including epithelial ovarian cancer, hepatocellular carcinoma (HCC), Anaplastic Thyroid Cancer (ATC) and pancreatic cancer. The drug candidate is fusion protein of a monoclonal antibody against EGFR with TGF beta 2 receptor fragment that binds and neutralizes TGF beta. It is developed based on technology platform which involves discovery and development of targeted immunoconjugates. It is administered intravenously. It acts by targeting EGFR and TGF beta. This program was also under development for the treatment of infectious diseases.
Bicara Therapeutics overview
Bicara Therapeutics, is a clinical-stage biotechnology company developing dual-action biologics designed to spur a potent and durable immune response in the tumor microenvironment. The company is headquartered in United States.
Quick View BCA-101 LOA Data
|Highest Development Stage|